One of the recurring themes at the recently-concluded Precision Medicine Leaders Summit in San Diego was how to digest the plethora of information available in healthcare. Whether it’s coming from next-generation sequencing, electronic health records or consumer devices, how do clinicians and patients make the data useful? “In chronic disease, if we don’t solve the problem of how to adapt these tools to clinical practice and patient care, we’re not going to make much progress,” said Michael Hodgkins, chief medical information officer at the American Medical Association, to the audience. “You can’t manage patients who have chronic diseases in the four walls of the clinic. You have to meet them where they live.”
San Francisco-based genetic diagnostics company Invitae has acquired Good Start Genetics and CombiMatrix, expanding Invitae’s portfolio to include prenatal and pediatric testing. It’s part of their long-term plan to make genomic testing routine.“We’re building a company for the coming genomic era that includes genetic capabilities through all phases of life,” said Invitae CEO Sean George in a phone interview.
As the precision medicine movement gains speed in healthcare, Philadelphia-based Penn Medicine is looking to take advantage of all it has to offer. Its efforts have undoubtedly been noteworthy. In January 2016, it founded the Penn Center for Precision Medicine, which focuses on precision medicine development and implementation efforts. The center has its own PCPM Accelerator Fund, which supports projects that test unique approaches to how precision medicine impacts patient care.